Latest News Archive

Please select Category, Year, and then Month to display items

Putting mental health in the spotlight through filmmaking

20 October 2022 | Story Gerda-Marié van Rooyen

Using her experience in theatre and her passion for students, Gali Mokgosi, Residence Head of House Madelief, helps students explore and implement skills to cope with the demands of university life. A Health and Wellness coordinator for residence life, she helps improve their lives by teaching them the value of sufficient sleep, nutrition, exercise, recreation, positive coping strategies, healthy social and sexual relationships, and a sense of belonging within residences.

Mentoring and supporting university students

As a former English lecturer for first-year students, this go-getter saw an urgency to mentor and support university students. In 2016, she landed a job as residence head and resigned from lecturing to focus on theatre and residence affairs. Soon after her appointment, she and her colleague, Nthabiseng Mokhethi, Residence Head of House Ardour, were asked to coordinate the Residence Life Health and Wellness portfolio at a time when there were many suicide attempts and mental health issues, and drug and alcohol abuse plagued residences.

“Our main responsibility as Health and Wellness coordinators is to support Residence Committee Health and Wellness representatives (RCHW) in their respective residences. We facilitate training for RCHW peers and help them to think broadly about how campus life inside and outside the classroom – including residence life – affects and is affected by the physical, mental, and spiritual health of its students.”

Using film to address topical issues

With an honours degree in Drama and Theatre Arts, this UFS alumna knew she had to adapt to virtual means for her portfolio to continue supporting students during COVID-19.

“There was a need for intervention, and I saw an opportunity to close this gap by helping students through their challenges using films. I wrote films that directly address the challenges students were/are facing. Being a residence head, content for my films is always under my nose, and the storyline is undeniably relevant to them.”

Mokgosi wrote and produced four films for the various student support offices, with the help of Shibashiba Moabelo, Institutional HIV/AIDS Programme Coordinator at Kovsie Health, and Pulane Malefane, Assistant Director: Residence Life. These films are, I am, Triggers, Versus me, and Monate jou lekker ding.

This scriptwriter says when students can identify themselves in a story, they tend to gravitate towards a solution as suggested by the story. Students across the University of the Free State’s (UFS) three campuses act in the films. After watching a film, students engage with each other and receive tools to explore the story and reflect on the outcomes as suggested by the film.

Proving her sensitivity for inclusiveness, she had an opportunity to be part of the art skills exchange programme in Deaf theatre at Gallaudet University, Washington, DC. She also presented a research paper in Athens, Greece.

Mokgosi is looking forward to experiment with Deaf films in 2023.

Asked how she looks after her mental health, she reveals: “I take care of my mental health through prayer and meditation. I believe the first place to prosper is through my spiritual life. God is my strength from day to day. He is my all in all. Without Him, I will fall.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept